20th International Congress » Parkinson's disease: Pathophysiology

12:30pm-2:00pm

α-synuclein CSF levels correlate with urinary dysfunction in early de novo Parkinson’s disease patients

G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

12:30pm-2:00pm

α-synuclein in peripheral organs decreases in Lewy body disease complicated by Alzheimer’s disease

H. Sumikura, J. Fujigasaki, Y. Nakano, A. Uchino, Y. Saito, H. Mochizuki, S. Murayama (Tokyo, Japan)

12:30pm-2:00pm

A comprehensive characterisation of the salivary proteome of patients with Parkinson’s disease

J.M. Masters, A.J. Noyce, S. Lynham, T.T. Warner, G. Giovannoni, G.B. Proctor (Herts, United Kingdom)

12:30pm-2:00pm

A novel C. elegans model for identification of small molecules that target alpha-synuclein-mediated toxicity

L.V. Kalia, K. Menezes, Y. Zhang, S. Ishikura, N. Tran, H. Chau, A.M. Lozano, S.K. Kalia, J.G. Culotti, S. Suo, W.S. Ryu (Toronto, ON, Canada)

12:30pm-2:00pm

A novel single molecule imaging approach to detect individual protein oligomers in CSF from patients with Parkinson’s disease (PD)

S. Gandhi, M.H. Horrocks, S.F. Lee, N.W. Wood, D. Klenerman (London, United Kingdom)

12:30pm-2:00pm

A whole brain anatomical network model and its application in PD research

X. Lei, T. Chen, X. Hu, B. Zhang (Kunming, People's Republic of China)

12:30pm-2:00pm

Alpha synuclein and crystallin expression in human lens in Parkinson’s disease

S.A. Schneider, E. Richert, G. Kuhlenbäumer, B. Nölle, K.P. Bhatia, G. Deuschl, J. Roider, A. Klettner (München, Germany)

12:30pm-2:00pm

Alpha-synuclein – super-resolution microscopy reveals potential new role of alpha-synuclein at the pre-synapse

J. Lautenschlaeger, F. Stroehl, A. Stephens, C.F. Kaminski, G.S. Kaminski Schierle (Cambridge, United Kingdom)

12:30pm-2:00pm

Alpha-synuclein gene variants may predict neurostimulation outcome

D. Weiss, S. Herrmann, L. Wang, C. Schulte, K. Brockmann, C. Plewnia, T. Gasser, M. Sharma, A. Gharabaghi, R. Krüger (Tübingen, Germany)

12:30pm-2:00pm

Alpha-synuclein in gastric and colonic mucosa in Parkinson’s disease: Limited role as a biomarker

S.J. Chung, J. Kim, H.J. Lee, H.S. Ryu, K.W. Jung, M.J. Kim, M.J. Kim, S.M. Hong, S.J. Myung (Seoul, Korea)

12:30pm-2:00pm

Alterations in 14-3-3 protein phosphorylation as a biomarker for neurodegeneration

T. Yacoubian, X. Chi, G. Cutter, M. McFerrin (Birmingham, AL, USA)

12:30pm-2:00pm

An exuberant cortical γb influences the unmasking and intensity of dyskinesia in 6-OHDA-treated freely-moving rats

S. Galati, V. D'Angelo, A. Salvadè, A. Kaelin, A. Stefani (Lugano, Switzerland)

12:30pm-2:00pm

Analysis of relationships between spinal deformity and walking ability in Parkinson’s disease patients

Y. Nakamura, Y. Machida, T. Hanawa, M. Kanai, K. Tajima, S. Asano (Satte, Japan)

12:30pm-2:00pm

Apathy phenotype in Parkinson’s disease: Motor and non-motor features

S. Varanese, A. Di Rocco, M.F. Ghilardi, N. Modugno, R. Gilbert-Wolf, B. Perfetti (Pozzilli, Italy)

12:30pm-2:00pm

APL-130277 is a sublingual film being studied in phase 3 trials to rapidly turn patients ON from OFF episodes by delivering apomorphine via the oral mucosa

H. Shill, E.J. Pappert, A. Agro, B. Dzyngel, T. Bilbault, R. Hauser, S. Isaacson (Phoenix, AZ, USA)

12:30pm-2:00pm

Association of Parkinson’s disease severity and cortical and subcortical cognitive markers

H. Duran-Meza, A.D. Santana-Vargas, J.D. Ramirez-Diossa, G.H. Terrazas Gonzalez, G. Millan-Rosas, U. Jimenez-Correa, M. Lopez-Ruiz (Mexico City, Mexico)

12:30pm-2:00pm

Associations between cerebrospinal fluid proteins and cytokines in Parkinson’s disease

R. Wijeyekoon, S. Moore, K. Farrell, D. Breen, R. Barker, C.H. Williams-Gray (Cambridge, United Kingdom)

12:30pm-2:00pm

Astroglia exert a neuro-protective role in Parkinson’s disease by reducing oxygen stress through dopamine-induced activation of the pentose-phosphate pathway

K. Mashima, S. Takahashi, T. Iizumi, T. Abe, N. Suzuki (Tokyo, Japan)

12:30pm-2:00pm

Bcr-Abl tyrosine-kinase inhibitors (B-ATKI) and Parkinson’s disease (PD)

E.A. Shamim, S.F. Baker, F.F. Liu, K.K. Mane, J.G. Layug, S. Vupputuri, C.C. DiStasio, S.M. Khandhar, C. Neff, S. Van Den Eeden, C. Lungu, R. Cooley, H.S. Martel, C. Chen, J. Dorman, M.A. Sinkiewicz, J. Klingman (Largo, MD, USA)

12:30pm-2:00pm

Bi-hemispheric phase synchronization in patients with Parkinson’s disease during stance, gait and upper limb motor tasks

M. Plotnik, Y. Miron, S. Hassin-Baer, O.S. Cohen, S. Kimel-Naor, I. Blatt, R. Inzelberg, J.W. Kantelhardt (Tel Hashomer, Israel)

12:30pm-2:00pm

Brain metabolic profile changes reflect subtle pathological alterations in different murine models of Parkinson’s disease

E. Glaab, F. Giesert, C. Jaeger, P. Dirscherl, A. Zimprich, A. Ulusoy, D.A. Di Monte, P. Garcia, R. Balling, W. Wurst, D. Truembach, M. Buttini, D. Vogt-Weisenhorn (Esch-Alzette, Luxembourg)

12:30pm-2:00pm

Carrier mediated delivery system bearing dopamine for effective management of parkinsonism

V. Bhargava, S. Bhargava (Kanpur, India)

12:30pm-2:00pm

Cell-surface expression of dopamine transporter facilitates the uptake of α-synuclein

J. Kobayashi, T. Hasegawa, S. Yoshida, N. Sugeno, R. Oshima, A. Kikuchi, A. Takeda, M. Aoki (Sendai, Japan)

12:30pm-2:00pm

Cellular senescence induced by paraquat drives neuropathology associated with Parkinson’s disease

S.J. Chinta, G. Woods, M. Demaria, J. Campisi, J.K. Andersen (Novato, CA, USA)

12:30pm-2:00pm

Cerebellar atrophy in Parkinson’s disease and its implication for network connectivity

J.M. Shine, C. O'Callaghan, M. Hornberger, G.M. Halliday, S.J.G. Lewis (Palo Alto, CA, USA)

12:30pm-2:00pm

Changes in serum amino acid levels with progression of Parkinson’s disease

M. Figura, K. Kusmierska, E. Bucior, S. Szlufik, D. Koziorowski, Z. Jamrozik, A. Friedman, P. Janik (Warsaw, Poland)

12:30pm-2:00pm

Characteristics of the interaction between different toxic aggregated species of alpha-synuclein and cell membrane

A.T. Marvian, D. Morshedi, F. Aliakbari, H. Ghapani, M. Nasuti (Tehran, Islamic Republic of Iran)

12:30pm-2:00pm

Characterization of striatal TH-immunoreactive cells in chronic and acute L-DOPA treatment in a mice model of Parkinson´s disease

G. Gomez, M. Bordone, S.I. Sanz-Blasco, M.A. Bernardi, J.E. Ferrario, I.R.E. Taravini, M.G. Murer, O.S. Gershanik (Buenos Aires, Argentina)

12:30pm-2:00pm

Chronic cerebral hypoperfusion accelerates cognitive dysfunction and microvascular impairment in the MPTP mouse model of Parkinson’s disease

H. Tang, R. Zhu, L. Gao, K. Nie, S. Feng, Z. Duan, Y. Zhang, X. Zhao, L. Wang, J. Zhao, Z. Huang, Y. Zhang, L. Wang (Guangzhou, People's Republic of China)

12:30pm-2:00pm

Circadian dysfunction in Parkinson’s disease: Effects on impaired gait initiation and locomotion

L. Alibiglou, J. Stewart, G. Bachman, C. Cooper, L. Liu, S. Ancoli-Israel (Chicago, IL, USA)

12:30pm-2:00pm

Clinical aspects of postural instability in Parkinson’s disease

T.S. Lovtsova, A.F. Vasilenko (Chelyabinsk, Russia)

12:30pm-2:00pm

Clinical predictors of airway protective dysfunction in Parkinson’s disease

M.S. Troche, A.E. Brandimore, B. Schumann, M.S. Okun, K.W. Hegland (New York, NY, USA)

12:30pm-2:00pm

Cognitive and depressive behavior changes in aged mice with heterozygous deletions of VMAT2 or of DAT

K. Ma, J. Huang, L. Liu, H. Jiang, X. Xu, C. Han, Y. Shen, Y. Xia, S. Guo, L. Wang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm

Colonic microbiome in Korean patients with Parkinson’s disease

D. Lee, Y.N. Kwon, T.B. Ahn (Seoul, Korea)

12:30pm-2:00pm

Constipation in early de novo Parkinson’s disease: Prevalence and correlates with clinical features, imaging and non-imaging biomarkers

G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

12:30pm-2:00pm

Cortical impairment as marker of dementia risk in probable REM sleep behavior disorder in Parkinson’s disease

A.D. Santana-Vargas, H. Duran-Meza, J.D. Ramirez-Diossa, G.H. Terrazas Gonzalez, M. Lopez-Ruiz, G. Millan-Rosas, U. Jimenez-Correa (Mexico City, Mexico)

12:30pm-2:00pm

Cortical role in the freezing of gait in Parkinson’s disease

M. Mihara, H. Otomune, H. Fujimoto, K. Konaka, Y. Watanabe, H. Mochizuki (Suita, Japan)

12:30pm-2:00pm

Counteracting PINK1/parkin deficiency by activating alternative mitophagic pathway: a potential therapeutic intervention for Parkinson’s disease

B. Koentjoro, J.S. Park, C.M. Sue (Sydney, Australia)

12:30pm-2:00pm

Cyclic glycine-proline increased in the cerebrospinal fluid of Parkinson’s patients after supplementation of blackcurrant anthocyanins: Potential biomarker for treatment

J. Guan, Y. Alamri, D. Fan, M. MacAskill, T. Anderson (Auckland, New Zealand)

12:30pm-2:00pm

Defective ubiquitinated mitochondria accumulation in aged Parkinsonian LRRK2^R1441G knockin mice

H.F. Liu, P.W.L. Ho, L.F. Li, G.C.T. Leung, C.S.C. Lam, M.H.W. Kung, D.B. Ramsden, S.L. Ho (Hong Kong, Hong Kong)

12:30pm-2:00pm

Detection of leucine-rich repeat kinase 2 in human biofluids

E. Mutez, W. Sibran, T. Comptdaer, P. Semaille, M. Drouyer, S. Bleuse, L. Defebvre, A. Destee, M.C. Chartier-Harlin, J.M. Taymans (Lille, France)

12:30pm-2:00pm

Difference of REM sleep behavior disorder between the onset of before and after Parkinson’s disease

T. Nomura, Y. Inoue, K. Nakashima (Yonago, Japan)

12:30pm-2:00pm

Differences between responders and non-responders of Istradefylline for the wearing off in Parkinson’s disease

A. Yoritaka, H. Mori, N. Hattori (Saitoma, Japan)

12:30pm-2:00pm

Differences of gut bacterial community relate to pathology progress in Parkinson’s disease

T. Minato, S. Hasegawa, Y. Fujisawa, H. Tsuji, T. Asahara, K. Nomoto, A. Okamoto, T. Maeda, K. Ohno, M. Hirayama (Nagoya, Japan)

12:30pm-2:00pm

Different patterns of spontaneous brain activity between tremor-dominant and postural instability/gait difficulty subtypes of Parkinson’s disease: A resting-state fMRI study

H. Chen, Z. Wang, J. Fang, L. Gao, T. Feng (Beijing, People's Republic of China)

12:30pm-2:00pm

Differential expression of cerebral dopamine neurotrophic factor (CDNF) in the hippocampus and in the striatum of LRRK-2 mutant rat model of Parkinson’s disease

J. Varghese, K. Terpstra, S. Chiu, R. Mishra, Y. Bureau (London, ON, Canada)

12:30pm-2:00pm

Differential vulnerability to α-synuclein pathology among neuronal subpopulations

E. Luna, D.M. Riddle, V.M.Y. Lee, K.C. Luk (Philadelphia, PA, USA)

12:30pm-2:00pm

Diffusion tensor imaging (DTI) within the primate caudate nucleus marks dopaminergic (DA) and serotonergic (5-HT) lesions

S. Thobois, E. Météreau, M. Beaudoin-Gobert, S. Duperrier, L. Tremblay, V. Sgambato-Faure (Bron, France)

12:30pm-2:00pm

Diffusion tensor imaging biomarkers of nigrostriatal neurodegeneration in early Parkinson’s disease

J.A. Pineda-Pardo, G. Foffani, J.A. Obeso (Madrid, Spain)

12:30pm-2:00pm

Discrimination of Parkinson’s disease participants from healthy controls using telephone-quality voice recordings

S. Arora, A. Tsanas (Oxford, United Kingdom)

12:30pm-2:00pm

Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease from OFF to fully ON

H. Shill, E.J. Pappert, A. Agro, B. Dzyngel, T. Bilbault, S. Isaacson, R. Hauser (Phoenix, AZ, USA)

12:30pm-2:00pm

Disruption of circadian rhythm function and anti-oxidation via SIRT1-BMAL1 pathway in 6-OHDA induced Parkinson’s disease model

Y. Wang, S. Li, C. Mao, Y. Yang, F. Wang, C.F. Liu (Suzhou, People's Republic of China)

12:30pm-2:00pm

DJ-1 regulates intracellular signaling in a highly cell type specific manner

F. Giesert, D.M. Vogt Weisenhorn, U. Hafen, A. Romanov, A. Kurz-Drexler, W. Wurst (Neuherberg, Germany)

12:30pm-2:00pm

Drp1 inhibition amelioratesα-synuclein-mediated neurodegeneration in rats

S. Bido, L. Arcuri, M. Helly, R. Fan, K. Tieu, E. Bezard (Bordeaux, France)

12:30pm-2:00pm

Dynamic and static posturographic analysis among fallers and non- faller Parkinson’s disease (PD) patients using Neurocom SMART EquiTest

A. Lieberman, C. Frames, A. Deep, M. McCauley, S. Shafer (Phoenix, AZ, USA)

12:30pm-2:00pm

Effect of intra-striatal 6-OHDA lesion on extra-striatal structures in the mouse

B. Becker, M. Demirbas, C. Beyer, S. Tan, M. Kipp (Aachen, Germany)

12:30pm-2:00pm

Effect of vibration on motor performance: A new intervention to improve bradykinesia in Parkinson’s disease?

A. Macerollo, C. Palmer, T. Foltynie, P. Korlipara, P. Limousin, M. Edwards, J. Kilner (London, United Kingdom)

12:30pm-2:00pm

Effects of Arachidonyl-2′-chloroethylamide (ACEA), a selective CB1 receptor agonist, in MPTP mouse model of Parkinson’s disease

M. Omidbeigi, S. Asaadi, A. Zali (Tehran, Islamic Republic of Iran)

12:30pm-2:00pm

Evaluation of regional changes in striatal DAT binding in a progressing Parkinson’s disease (PD) cohort: Lessons for imaging biomarker assessment in disease-modifying therapeutic trials

J.P. Seibyl, D. Jennings, K. Marek (New Haven, CT, USA)

12:30pm-2:00pm

Evaluation of the role of oxidative stress in Parkinson’s disease and Parkinson plus syndrome

R. Qadri, M.A. Faiq, M. Behari, V. Goyal, A.K. Mukhopadhyay (New Delhi, India)

12:30pm-2:00pm

Exosomes-injection to reproduce a mouse model of Parkinson’s disease: A preliminary report

C. Han, J. Huang, K. Ma, Y. Shen, L. Liu, G. Zhang, X. Xu, J. Li, H. Jiang, S. Guo, Y. Xia, L. Wang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm

Exploring aging-VMAT2 gene-rotenone interactions in a cell model for Parkinson’s disease

H. Jiang, J. Li, C. Han, K. Ma, L. Liu, Y. Shen, L. Wang, S. Guo, Y. Xia, J. Huang, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm

F1 crossbreds of C57BL/6 and CD-1 mice demonstrate resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced nigral neurodegeneration

P.A. Alladi, D. Vidyadhara, H. Yarreiphang, T.R. Raju (Bengaluru, India)

12:30pm-2:00pm

Falls in Parkinson’s disease: Beware the short, slow steps

A. Lieberman, A. Deep, S. Shafer, T. Lockhart (Phoenix, AZ, USA)

12:30pm-2:00pm

Floor square size predicts step count of 360° turns in PD patients with freezing

U.M. Fietzek, L. Stuhlinger, A. Plate, A.O. Ceballos-Baumann, K. Bötzel (Munich, Germany)

12:30pm-2:00pm

Gait impairment is more than a motor symptom in Parkinson’s disease

H.F. Chan, D.K.W. Chau, T. Fung, Y.F. Cheung, W.C. Fong (Hong Kong, Hong Kong)

12:30pm-2:00pm

Gender-age features of autonomic heart rhythm disturbances in Parkinson’s disease patients

I. Solodovnikova (Odessa, Ukraine)

12:30pm-2:00pm

Gene expression analysis using the Parkinson’s disease map reveals early effects of alpha-synuclein on PD pathogenesis

S. Gebel, A. Ashrafi, P. Garcia, M. Ostaszewski, P. Gawron, L. Vallar, N. Nicot, T. Kaoma, R. Balling, E. Glaab, M. Buttini (Esch-sur-Alzette, Luxembourg)

12:30pm-2:00pm

Generation and characterization of midbrain organoids from iPSCs of familial Parkinson’s disease

E. Frattini, G. Monzio Compagnoni, S. Salani, P. Rinchetti, M. Nizzardo, M. Baccarin, N. Bresolin, G.P. Comi, S.P. Corti, A. Di Fonzo (Milan, Italy)

12:30pm-2:00pm

Generation of dopaminergic neurons for studying Parkinson’s disease using patient blood cells

D. Ma, W. Zhou, Y. Chao, Y. Zhao, E.K. Tan (Singapore, Singapore)

12:30pm-2:00pm

Glatiramir acetate (Copaxone) causes restoration of the striatal dopamine in a progressive MPTP mouse model of Parkinson’s disease

C.K. Meshul, M.J. Churchill (Portland, OR, USA)

12:30pm-2:00pm

Glucocerebrosidase activity in a cohort of PD patients

I. Trezzi, V. Melzi, G. Franco, L. Borellini, E. Monfrini, A. Bordoni, N. Bresolin, G.P. Comi, A. Di Fonzo (Milan, Italy)

12:30pm-2:00pm

Glutathione status in Parkinson’s disease

L.K. Mischley (Kenmore, WA, USA)

12:30pm-2:00pm

Heterozygous PINK1 p.G411S mutation increases risk for Parkinson’s disease (PD)

W. Springer, A. Puschmann, F.C. Fiesel, M. Ando, T.R. Caulfield, K. Ogaki, M.G. Heckman, R. Hudec, E.D. James, G. Opala, J. Siuda, M. Boczarska-Jedynak, A. Friedman, D. Koziorowski, J.O. Aasly, T. Lynch, G.D. Mellick, M. Mohan, P.A. Silburn, Y. Sanotsky, C. Vilariño-Güell, M.J. Farrer, T. Dawson, Z.K. Wszolek, O.A. Ross (Jacksonville, FL, USA)

12:30pm-2:00pm

Histone deacetylase 4 is regulated by microRNA 128 in SH-SY5Y cells of Parkinson’s disease

J. Li, N. Xiong, H. Jiang, L. Liu, C. Han, K. Ma, X. Xu, Y. Shen, Y. Xia, L. Wang, S. Guo, J. Huang, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm

Hyperin inhibits lipopolysaccharide-induced microglia activation through p38 and NFκB signaling

X. Zhang, Y.N. Wang, H.H. Fan, R. Yang, S.Y. Li, J.H. Zhu (Wenzhou, People's Republic of China)

12:30pm-2:00pm

Identifying freezing of gait and falls in Parkinson’s disease patients using a body-worn sensor

Y. Okuma, H. Mitoma, M. Yoneyama (Izunokuni, Japan)

12:30pm-2:00pm

IL-6 and motor symptoms in Parkinson’s disease

T. Torgan, T. Baidina, N. Demchuk, M. Danilova (Perm, Russia)

12:30pm-2:00pm

Impact of prolonged temporal discrimination threshold on finger movements of Parkinson’s disease

M.J. Lee, J.S. Son, J.H. Lee, S.J. Kim, C.H. Lyoo, M.S. Lee (Busan, Korea)

12:30pm-2:00pm

Impairments in trunk muscle function influence head and trunk stability during walking in Parkinson’s disease fallers

M.H. Cole, G.A. Naughton, P.A. Silburn (Virginia, Australia)

12:30pm-2:00pm

In idiopathic Parkinson’s disease: The effect of using L-dopa on peripheral nerves

M.E. Temir, F. Genç, Y. Biçer Gömceli, A. Yaman, A. Aybar, E. Karaçay (Antalya, Turkey)

12:30pm-2:00pm

Increased anti-MAG autoantibodies titers in Parkinson’s disease

E. Papuc, K. Rejdak (Lublin, Poland)

12:30pm-2:00pm

Increased cellular co-localization of tau fragment 1-368 and alpha-synuclein in two mouse model of Parkinson’s disease

K. Ma, S. Nie, G. Chen, C. Han, X. Guo, Y. Xu, X. Cao (Wuhan, People's Republic of China)

12:30pm-2:00pm

Increased energy expenditure in early Parkinson’s disease during exercise

T. Margaliot Kalifa, N. Ziv, H. Bergman, S. Nusair, D. Arkadir (Jerusalem, Israel)

12:30pm-2:00pm

Influence of levodopa on functional brain connectivity in Parkinson’s disease

S. Kobayashi, K. Asano, N. Matsuda, H. Kubo, M. Abe, Y. Ugawa (Fukushima-shi, Japan)

12:30pm-2:00pm

Integrity of the superior longitudinal fascicle and its relationship with anticipatory postural adjustments in people with Parkinson’s disease and freezing of gait

A.C. de Lima-Pardini, T.Q. Freitas, D.B. Coelho, C.C. Boffino, C. Souza, R. Brandt, E.R. Barbosa, L.A. Teixeira, E. Amaro Jr. (São Paulo, Brazil)

12:30pm-2:00pm

Intrastriatal injection of ionomycin profoundly changes motor response to L-DOPA and its underlying molecular mechanisms

C. Han, S. Nie, G. Chen, K. Ma, N. Xiong, Z. Zhang, Y. Xu, T. Wang, S.M. Papa, X. Cao (Wuhan, People's Republic of China)

12:30pm-2:00pm

Investigating the role of Parkin in mitigating oxidative stress

J.M. Tokarew, D. El Kodsi, J.T. Tomlinson, M.G. Schlossmacher (Ottawa, ON, Canada)

12:30pm-2:00pm

Involvement of peripheral immune system in the pathogenesis of Parkinson’s disease

Y.X. Chao, S.C. Wong, K.J. Puan, J.J.Y. Tai, O. Rötzschke, B. Lee, M. Poidinger, E.K. Tan (Singapore, Singapore)

12:30pm-2:00pm

Is levodopa-induced dyskinesia in Parkinson’s disease associated with increased blood brain barrier permeability and volumetric changes?

O. Segal, D. Last, D. Guez, Y. Mardor, G. Yahalom, O.S. Cohen, S. Benizri, C. Hoffman, S. Hassin-Baer (Ramat Gan, Israel)

12:30pm-2:00pm

Is the assessment of 5 meters of gait with body-worn-sensors enough to recognize Parkinsonian gait?

M.E. Micó Amigo, I. Kingma, A. Kunikoshi, R.V. Lummel, W. Maetzler, J.V. Dieën (Amsterdam, Netherlands)

12:30pm-2:00pm

Kinematic analysis of repetitive finger movements and the effects of selegiline and pramipexole in early Parkinson’s disease

G. Leodori, M. Bologna, P. Stirpe, G. Paparella, D. Belvisi, A. Fasano, G. Fabbrini, A. Berardelli (Rome, Italy)

12:30pm-2:00pm

LC3 deacetylation by SIRT1 is involved in neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson’s disease

Y. Wu, Y. Guo, S. Dong, X. Cui, Y. Feng, W. Zhao (Shanghai, People's Republic of China)

12:30pm-2:00pm

Lessons learned from the Nilotinib trial: Cardio-vascular conditions in parkinsonism

Y. Torres-Yaghi, A. Keys, V. Ellen, S. Ashot, M. Elizabeth, S. Justin, M. Charbel, P. Fernando (Washington, DC, USA)

12:30pm-2:00pm

Lewy body extracts from Parkinson’s disease brains as models for high-throughput screens of neurotoxicity and α-synuclein spreading from cell-to-cell

E. Bezard, F. Cavaliere, P. Kitchener, E.Y. Pioli, B. Dehay, M. Bourdenx, P. Ramos-Gonzalez, J. Obeso, C. Matute (Bordeaux, France)

12:30pm-2:00pm

Localization and functional study of synaptic vesicle protein synaptogyrin-3 (SYNGR3) on dopaminergic neuronal system

L.F. Li, P.W.L. Ho, H.F. Liu, Z.H.M. Tse, C.S.C. Lam, M.C.T. Leung, M.H.W. Kung, D.B. Ramsden, S.W.L. Ho (Hong Kong, People's Republic of China)

12:30pm-2:00pm

Long-duration response to levodopa in Parkinson’s disease is independent of disease duration: A prospective study on de novo patients in Ghana

R. Cilia, E. Cereda, M. Amboni, A. Akpalu, F.S. Sarfo, M. Cham, M. Fabbri, G. Pezzoli (Milan, Italy)

12:30pm-2:00pm

Longitudinal cerebrospinal fluid biomarkers in early Parkinson’s disease and healthy controls

B. Mollenhauer, C.J. Caspell-Garcia, C.S. Coffey, P. Taylor, L.M. Shaw, J.Q. Trojanowski, A. Singleton, M. Frasier, K. Marek, D.R. Galasko (Kassel, Germany)

12:30pm-2:00pm

Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s disease

S. Hall, Y. Surova, A. Öhrfelt, K. Blennow, H. Zetterberg, O. Hansson (Lund, Sweden)

12:30pm-2:00pm

Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype

I. Huertas Fernandez, S. Jesus, J.A. Lojo, F.J. Garcia Gomez, M. Caceres Redondo, J.M. Oropesa Ruiz, F. Carrillo, L. Vargas Gonzalez, J.F. Martin Rodriguez, P. Gomez Garre, D. Garcia Solis, P. Mir (Sevilla, Spain)

12:30pm-2:00pm

Lrrk2 alleles modify host response to microbial infections

B. Shutinoski, I. Harmsen, M. Hakimi, Y.Y. Zhou, S. Sad, J.J. Tomlinson, E.G. Brown, M.G. Schlossmacher, CLINT Investigators (Ottawa, ON, Canada)

12:30pm-2:00pm

Lymphocytes have a detrimental effect on motor behavior in the AAV1/2 A53T α-synuclein mouse model of Parkinson’s disease

A.A. Karikari, M. Gehmeyr, E. Ribechini, V. Maltese, J. Volkmann, J.M. Brotchie, J.B. Koprich, M.B. Lutz, C.W. Ip (Würzburg, Germany)

12:30pm-2:00pm

Micro-RNA in cerebrospinal fluid as a biomarker for early diagnosis, differential diagnosis and prognostic marker in Parkinson’s disease

A. Fischbach, A.E. Roser, F. Maass, M. Börger, M. Bähr, I. Zerr, A. Fischer, P. Lingor (Göttingen, Germany)

12:30pm-2:00pm

Microglia P2Y6 receptor is related to Parkinson’s disease and involved in the neuroinflammatory process

X. Yang, Y. Lou, X. Wang, G. Liu, Y. Qian, J. Ding, S. Chen, Q. Xiao (Shanghai, People's Republic of China)

12:30pm-2:00pm

Mild mitochondrial impairment promotes corticostriatal synaptic plasticity alterations in PINK1 heterozygous knockout mice

P. Imbriani, G. Martella, G. Madeo, M. Maltese, V. Vanni, E. Ferraro, E.M. Valente, T. Schirinzi, L. Bonanni, J. Shen, N.B. Mercuri, P. Bonsi, A. Pisani (Rome, Italy)

12:30pm-2:00pm

Minimum MDS-UPDRS part III change needed to convert a Parkinson’s disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277)

H. Shill, A. Agro, E.J. Pappert, B. Dzyngel, T. Bilbault, S. Isaacson, R. Hauser (Phoenix, AZ, USA)

12:30pm-2:00pm

Mitochondrial dysfunction in skin fibroblasts from single heterozygous ATP13A2 (PARK9) mutation carriers

J.S. Park, C. Klein, C.M. Sue (St. Leonards, Australia)

12:30pm-2:00pm

Mitochondrial Hsp90 inhibitor G-TTP triggers PINK1/parkin-dependent mitochondrial quality control

F.C. Fiesel, J.D. Elle, H.R. Anneliese, H. Roman, S. Wolfdieter (Jacksonville, FL, USA)

12:30pm-2:00pm

Mitochondrial response precedes intracellular accumulation of α-synuclein in Parkinson’s disease

I. Milenkovic, E. Dassler, M. Weber, G.G. Kovacs (Vienna, Austria)

12:30pm-2:00pm

Mitochondrial-nuclear interplay in single respiratory chain-deficient Parkinson’s disease neurons

A. Grünewald, K.A. Rygiel, P.D. Hepplewhite, C.M. Morris, M. Picard, D.M. Turnbull (Belvaux, Luxembourg)

12:30pm-2:00pm

Modulating neuronal activity in dopaminergic neurons to promote their survival

M.A. Bernardi, N. Baffa-Trasci, O. Gershanik, M.E. Avale, J.E. Ferrario (Caba, Argentina)

12:30pm-2:00pm

Modulation of microglia function in the prion-like spreading of α-synuclein in the murine brain

W.M. Wemheuer, P. Garcia, E. Konica, A. Masuch, S. Brioschi, K. Biber, A. Weihofen, H. Kollmus, K. Schughart, D. Coowar, R. Balling, M. Buttini (Esch-sur-Alzette, Luxembourg)

12:30pm-2:00pm

Molecular landscape of Parkinson’s disease reveals a key role for lipids and lipoproteins

C.J.H.M. Klemann, G.J.M. Martens, M. Sharma, M.B. Martens, O. Isacson, T. Gasser, J.E. Visser, G. Poelmans (Nijmegen, Netherlands)

12:30pm-2:00pm

Multidisciplinary group program integrating voice and dance movement therapy for Parkinson’s disease patients: Preliminary experience

R. Peled, D. Shpunt, Y. Manor, M. Brozgol, A. Ezra, N. Hezi, R. Hen Simon, J.M. Hausdorff, T. Gurevich (Tel Aviv, Israel)

12:30pm-2:00pm

Neurodegeneration and microgliosis are independent of α-synuclein aggregation in a mouse model of "prion-like" α-synuclein speading

P. Garcia, W. Wemheuer, S. Brioschi, A. Masuch, E. Masliah, V. Koziel, T. Pillot, E. Koncina, C. Jaeger, A. Weihofen, R. Balling, K. Biber, M. Buttini (Esch-sur-Alzette, Luxembourg)

12:30pm-2:00pm

Neuromelanin imaging is useful for monitoring disease progression in Parkinson’s disease and PARK2

T. Hatano, A. Okuzumi, K. Kamagata, K. Daida, D. Taniguchi, M. Hori, H. Yoshino, S. Aoki, N. Hattori (Tokyo, Japan)

12:30pm-2:00pm

Non-motor symptoms profiles in UK white Caucasian and Asian as well as overseas Thai and East Indian patients with Parkinson’s disease

A. Sauerbier, O. Jitkritsadakul, R. Bhidayasiri, H. Kumar, P. Martinez-Martin, R. Banerjee, M. Kulsum, A. Rizos, G. Harington, L. Perkins, T. Chiwera, D. Trivedi, A. Martin, M. Parry, R. Brown, J. Al-Hashel, W. Kamel, A. Kilany, S. Lim, A. Tan, K. Bhattacharyya, R. Walker, K. Ray Chaudhuri, On behalf of EUROPAR, the MDS Non-Motor PD Study Group and the NILS Group (London, United Kingdom)

12:30pm-2:00pm

Objective methods for quantifying the deep brain stimulation (DBS) efficacy in subthalamic-nuclei (STN) neurons with microelectrode recording (MER) technology

V.R. Rama Raju, R.K. Mridula, R. Borgohain, V. Rama Raju (Hyderabad, India)

12:30pm-2:00pm

Olfaction and gray matter volume in Parkinson’s disease. A voxel-based morphometry study

K. Witt, N. Schmidt, O. Granert, L. Paschen, S. Wolff, G. Deuschl (Kiel, Germany)

12:30pm-2:00pm

Opioid K receptor variant delays the onset of dyskinesias in Parkinson’s disease

R. Cilia, R. Asselta, R. Benfante, E. Cereda, D. Vallauri, L. Marabini, D. Fornasari, S. Goldwurm, G. Pezzoli (Milan, Italy)

12:30pm-2:00pm

Optimization of 6-hydroxydopamine animal model of early stage Parkinson´s disease for the assessment of neurorestorative therapies

J.V. Leikas, T.M. Kääriäinen, A.J. Jalkanen, M. Lehtonen, T. Rantamäki, M.M. Forsberg (Kuopio, Finland)

12:30pm-2:00pm

Oral apomorphine film (APL-130277) produces no buccal mucosal irritation: Results of a toxicological study

A. Agro, B. Dzyngel, T. Bilbault, E.J. Pappert (Toronto, ON, Canada)

12:30pm-2:00pm

Parkinson’s disease motor subtypes show similar deficits in inhibitory control

C.M. Tolleson, M. Turchan, N. van Wouwe, S.A. Wylie (Nashville, TN, USA)

12:30pm-2:00pm

Parkinson’s disease onset on non-dominant side predicts greater motor disability

T.A. Finseth, S. Sillau, B. Berman (Aurora, CO, USA)

12:30pm-2:00pm

Pathophysiological mechanisms of bone mass loss for osteoporosis prevalence in Parkinson’s disease

L.A. Leandro, H.A.G. Teive (Curitiba, Brazil)

12:30pm-2:00pm

Pharmacokinetic-pharmacodynamic effects of apomorphine sublingual film (APL-130277) for the rapid management of OFF episodes in patients with Parkinson’s disease

E.J. Pappert, B. Dzyngel, T. Bilbault, A. Agro (Toronto, ON, Canada)

12:30pm-2:00pm

Physical training prevents depressive-like behavior and bdnf decrease in an animal model of Parkinson’s disease

T. Tuon, S.S. Valvasori, J.L. Quevedo, C.T. Souza, R.A. Pinho (Criciúma, Brazil)

12:30pm-2:00pm

PINK1-dependent clearance of depolarized mitochondria is driven by the UPS and can occur independently of (macro)autophagy

A. Rakovic, J. Ziegler, C.U. Mårtensson, J. Prasuhn, K. Shurkewitsch, P. König, H.L. Paulson, C. Klein (Luebeck, Germany)

12:30pm-2:00pm

Piper longum L. alkaloids inhibit lipopolysaccharide-stimulated microglial activation and protect nigral dopaminergic neurons

H. Yang, C. Duan (Beijing, People's Republic of China)

12:30pm-2:00pm

Postural and nonmotor disturbances in Parkinson’s disease

A. Pilipovich, V. Golubev, G. Ptimat (Moscow, Russia)

12:30pm-2:00pm

Pre-formed fibrils injection worsen pathology caused by AAV-mediated over expression of α-synuclein

L.S. Breger, P. Thakur, O.W. Wan, B. Mattsson, K. Luk, V.M. Lee, J. Trojanowski, A. Björklund (Lund, Sweden)

12:30pm-2:00pm

Presynaptic dopamine depletion predicts late complications and time of progression to advanced disease in patients with early Parkinson’s disease

R. Djaldetti, L. Greenbaum, M. Lorberboym (Petah Tiqva, Israel)

12:30pm-2:00pm

Protein levels of SV2A and VGLUT1 in brain tissue from patients with Parkinson’s disease, dementia with Lewy bodies and Alzheimer’s disease

S. Frykman, M. Oosterhof, M.S. Ahmed, D. Howlet, T. Hortobagyi, P. Francis, D. Årsland (Huddinge, Sweden)

12:30pm-2:00pm

Quantifying daily living transitions in patients with Parkinson’s disease using a body-fixed sensor

J.M. Hausdorff, H. Bernad-Elazari, T. Herman, A. Mirelman, E. Gazit, N. Giladi (Tel Aviv, Israel)

12:30pm-2:00pm

Reach-to-grasp impairments of both hands in individuals with Parkinson’s disease

S. Khacharoen, J. Tretriluxana, A. Pisarnpong, P. Chaiyawat (Nakhon Pathom, Thailand)

12:30pm-2:00pm

Relationships of cognitive functions and psychiatric symptoms with motor phenotypes in patients with untreated early-stage Parkinson’s disease

H. Terashi, Y. Ishimura, T. Taguchi, H. Mitoma, H. Aizawa (Tokyo, Japan)

12:30pm-2:00pm

Role of dopamine and GABA during subthalamic and pallidal deep brain stimulation: Evidence of dopamine release during subthalamic Deep Brain Stimulation

A. Nakajima, Y. Shimo, T. Uka, N. Hattori (Tokyo, Japan)

12:30pm-2:00pm

Role of macroautophagy in regulating microglia-mediated neuroinflammation and dopaminergic neuron injury

M. Jin, L. Hu, C. Liu (Suzhou, People's Republic of China)

12:30pm-2:00pm

Saliva swallowing frequency measured using 24-hours ambulatory impedance-pH monitoring in patients with Parkinson’s disease and drooling

J.G. Kalf, S. Scholten, W. Hopman (Nijmegen, Netherlands)

12:30pm-2:00pm

Selenotranscriptomic analyses identify signature selenoproteins in brain regions in a mouse model of Parkinson’s disease

J.Y. Wang, X. Zhang, Y.L. Ye, H.H. Fan, H.M. Wu, W.H. Cheng, J.H. Zhu (Wenzhou, People's Republic of China)

12:30pm-2:00pm

Sodium butyrate attenuates rotenone-induced neurodegeneration via enhancing autophagy and preventing α-synuclein aggregation

L. Liu, C. Han, K. Ma, X. Xu, J. Huang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm

Sonographic investigation of Pisa syndrome in Parkinson’s disease

J. Shiraishi, T. Okazaki, M. Mizuba, K. Kajiwara, S. Saeki, R. Matsugaki, T. Takei, T. Uozumi (Fukuoka, Japan)

12:30pm-2:00pm

Speed and severity of toxicity induced by pre-formed α-synuclein fibrils in rat brain is enhanced by α-synuclein overexpression

P. Thakur, L. Breger, B. Mattsson, K. Luk, V.M. Lee, J. Trojanowski, A. Björklund (Lund, Sweden)

12:30pm-2:00pm

Stabilometry characteristics as objective Parkinson’s disease progression biomarkers

I.V. Miliukhina, T.V. Sergeev, E.V. Gracheva, A.V. Kudrevatykh, M.D. Didur (Saint-Petersburg, Russia)

12:30pm-2:00pm

Staging and clinical correlates of cortical thinning in Parkinson’s disease

H. Wilson, F. Niccolini, C. Pellicano, P. Piccini, M. Politis (London, United Kingdom)

12:30pm-2:00pm

Striatal PDE10 expression in Parkinson’s disease (PD) and healthy controls using [¹⁸F]MNI-659 PET imaging

D.S. Russell, D.L. Jennings, O. Barret, G.D. Tamagnan, D. Alagille, J.P. Seibyl, K.L. Marek (New Haven, CT, USA)

12:30pm-2:00pm

Synaptic homeostasis in Parkinson’s disease: An high-density EEG study in different stage of the disease

S. Galati, S. Sarasso, C. Moeller, A. Kalein-Lang, C. Staedler (Lugano, Switzerland)

12:30pm-2:00pm

The contribution of the subthalamic nucleus in gait initiation of subjects with Parkinson’s disease

C. Palmisano, G. Arnulfo, N.G. Pozzi, A. Canessa, A. Leporini, C.A. Frigo, G. Pezzoli, F. Steigerwald, J. Volkmann, I.U. Isaias (Wuerzburg, Germany)

12:30pm-2:00pm

The correlation between N30 SEP and motor function in Parkinson’s disease

S.Y. Kang, Y.J. Kim, Y.H. Sohn, H.I. Ma (Hwaseong, Korea)

12:30pm-2:00pm

The effect of STN-DBS on movement initiation control is modulated by the noradrenergic system: Evidence of an interaction from a combined pharmacological/DBS/EEG study

C. Spay, M. Albares, S. Thobois, E. Broussolle, P. Boulinguez, B. Ballanger (Bron, France)

12:30pm-2:00pm

The effects of viral priming on neurotoxin induced neurodegeneration and synapse dysfunction in cell culture models relevant to Parkinson’s disease

L.K. Olsen, E. Dowd, D. McKernan (Galway, Ireland)

12:30pm-2:00pm

The epigenetic regulation of HIF-1α by SIRT1 in MPP+ treated SH-SY5Y cells

Y. Wu, S. Dong, Y. Guo, Y. Feng, X. Cui, S. Kuo, T. Liu (Shanghai, People's Republic of China)

12:30pm-2:00pm

The kinase Fyn mediates levodopa induced dyskinesias in Parkinson´s disease

J.E. Ferrario, S. Sanz-Blasco, M. Bordone, A. Damianich, A. Bernardi, G. Gomez, I. Taravini, E. Avale, O. Gershanik (Buenos Aires, Argentina)

12:30pm-2:00pm

The small GTP-binding protein Rhes influences midbrain dopaminergic neurons: Behavioral and biochemical studies

A. Pinna, F. Napolitano, G. Costa, P.F. Porceddu, L. Contu, J. Wardas, M.A. Casu, A. Usiello, M. Morelli (Cagliari, Italy)

12:30pm-2:00pm

Toward a new biomarker on Parkinson’s disease: Study of alpha synuclein on upper enteric system by endoscopy

N. Ben Ali, S. Mrabet, S. Hawet, R. Debbiche, S. Belal (Tunis, Tunisia)

12:30pm-2:00pm

Treatment of OFF episodes in Parkinson’s disease: An evaluation of patient and caregiver insights

E.J. Pappert, N. deGruyther, A. Agro (Toronto, ON, Canada)

12:30pm-2:00pm

Treatment of OFF episodes in Parkinson’s disease: An evaluation of physician practices

E.J. Pappert, A. Agro, N. deGruyther (Toronto, ON, Canada)

12:30pm-2:00pm

Urate and homocysteine: Changes in motor and cognitive symptoms in newly diagnosed Parkinson’s disease

I.J. Sleeman, R. Lawson, A. Yarnall, G. Duncan, F. Johnston, T. Khoo, D. Collerton, J.P. Taylor, D. Burn (Newcastle upon Tyne, United Kingdom)

12:30pm-2:00pm

Vagus nerve stimulation as a novel treatment strategy for Parkinson’s disease

A. Farrand, R. Gregory, K. Helke, S. Hays, V. Hinson, H. Boger (Charleston, SC, USA)

12:30pm-2:00pm

Vascular degeneration in Parkinson’s disease

J. Guan, P. Yang, R.L.M. Faill, M. Dragunow, H.J. Waldvogel (Auckland, New Zealand)

12:30pm-2:00pm

Vitamin D in early Parkinson’s disease

I.M. Sleeman, T. Aspray, S. Coleman, G. Duncan, T.K. Khoo, I. Schoenmakers, L. Rochester, D.J. Burn, A.J. Yarnall (Newcastle, United Kingdom)